Extracellular vesicle-mediated co-delivery of TRAIL and dinaciclib for targeted therapy of resistant tumors
Changhong Ke, Huan Hou, Kui Su, Chaohong Huang, Qian Yuan, Shuyi Li, Jianwu Sun, Yue Lin, Chuanbin Wu, Yu Zhao, Zhengqiang Yuan
Abstract
when compared with other treatments. The augmented therapeutic efficacy appeared to be associated with the concomitant suppression of prosurvival CDK1 and anti-apoptotic proteins including CDK9, cFLIP, MCL-1, BCL-2 and Survivin by Dina@EV-T treatment. Additionally, there were no adverse side effects observed for the systemic Dina@EV-T therapy. In conclusion, our data suggest that the co-delivery of TRAIL and Dina by EVs potentially constitutes a novel tumour-targeted therapy, which is highly effective and safe for the treatment of refractory tumors.
Topics & Concepts
SurvivinCancer researchApoptosisChemistrySystemic administrationCancerMedicineIn vivoBiologyInternal medicineBiochemistryBiotechnologyExtracellular vesicles in diseasePhagocytosis and Immune RegulationNanoplatforms for cancer theranostics